Skip to main content
. Author manuscript; available in PMC: 2015 Oct 16.
Published in final edited form as: Nature. 2015 Mar 9;520(7547):373–377. doi: 10.1038/nature14292

Figure 1. RT + anti-CTLA4 promotes regression of irradiated and unirradiated tumors and is inhibited by PD-L1 on tumor cells.

Figure 1

a) Waterfall plot of unirradiated tumors after RT to a single index lesion with anti-CTLA4. Dashed lines are thresholds for PD (red) and PR (blue). * Patients with new lesions. ** Clinical progression without imaging. b) PET/CT images of irradiated (white arrows) and unirradiated (yellow arrows) tumors from patient PT-402. c) PFS and OS for all patients (dashed lines: 95% CI). d) B16-F10 tumor growth after RT to the index tumor (n=8), anti-CTLA4 (C4) (n=9), anti-CTLA4 and RT to the index tumor (n=18), or no (control) treatment (n=9). The p-values are comparisons with control. Pie chart shows %CRs (yellow). See Fig. 2d for survival. e) Heat map showing relative abundance of immune cells or their ratios from tumors that are resistant (black hatch) or sensitive to RT + anti-CTLA4. Boxplot shows bootstrap importance scores for each variable. Higher values (red) are more predictive. f) Change in T cell subsets or their ratio after RT + anti-CTLA4 for sensitive parental (Sen) or resistant (Res) tumors. Values are subtracted from average of untreated controls. Red line is mean. g) Heat map of resistance gene signature and PD-L1 across human melanoma. p < 0.001 by gene set enrichment analysis. h) Expression of PD-L1 on Res 499 compared to B16-F10 melanoma cells and of Res 237 compared to TSA breast cancer cells. Isotype control (IgG). i) Total tumor volume from PD-L1 knockout (KO) or control (WT) Res 499 and corresponding survival.